Objective To summarize the experiences of combination transcatheter arterial chemoembolization (TACE) with radiofrequency ablation (RFA) in treatment of hepatocellular carcinoma (HCC). Methods This review analyzed data of 200 cases of patients from 2009 to 2015 treated by transcatheter arterial chemoembolization (TACE) with RFA. We also analized survival rate through Kaplan-Meier method. Results The group tumor included patients with diameter ≤3.0 cm, 3.1-5.0 cm, 5.1-7.0 cm and 7.1-10.0 cm, respectively sharing 22.5%, 30.5%, 32.0%, 15.0%. Frequency of treatment with TAE/TACE are totally 425 times, average 2.13 times per person. Patients recieved TAE/TACE followed by general anesthesia and percutaneous puncture through CT. The first totally RFA rates were respectively 100%, 78.3%, 28.1% and 0 in patients with tumor′s diameter ≤3.0 cm, 3.1-5.0 cm, 5.1-7.0 cm, 7.1-10.0 cm. When patients finished the whole therapeutics, the accumulational completed RFA rates was almost 96.5%. The accumulation survival rates were respectively 97.7%, 79.9%, 55.4% in years 1, 3 and 5. Conclusion TAE/TACE with RFA as a local treatment had a certain therapeutic effect, and it is more effective for the tumor′s diameter≥5 cm.%目的：总结介入栓塞（TAE/TACE）和射频消融（RFA）联合应用治疗原发性肝细胞癌（HCC）疗效的初步经验。方法回顾性分析作者2009—2015年连续收治的以联合应用TAE/TACE和RFA为主要治疗手段的200例HCC患者的临床资料，采用Kaplan-Meier法分析生存率。结果本组癌灶直径≤3.0 cm、3.1～5.0 cm、5.1～7.0 cm和7.1～10.0 cm者分别占22.5%、30.5%、32.0%和15.0%。患者应用TAE/TACE共425次，人均2.13次。患者应用TAE/TACE后均采用全身麻醉CT定位经皮穿刺，对于直径≤3.0 cm、3.1～5.0 cm、5.1～7.0 cm和7.1～10.0 cm的肝癌，第1次RFA的完全消融率分别为100.0%、78.3%、28.1%和0，经过序贯治疗后，累积完全消融率达到96.5%。本组1、3、5年的累积生存率分别为97.7%、79.9%、55.4%。结论 TAE/TACE和RFA联合、序贯、反复应用是两者互补疗效确定的局部治疗方案，更适合癌灶直径≥5 cm者。
展开▼
